胰激肽原酶肠溶片联合依帕司他胶囊治疗糖尿病周围神经病变患者的效果  

Effects of Pancreatic kininogenase enteric-coated tablets combined with Epalrestat capsules in treatment of patients with diabetic peripheral neuropathy

作　　者：王义范 WANG Yifan(Ward II of Department of Endocrinology of Henan Pingmei Shenma Medical Group General Hospital,Pingdingshan 467500 Henan,China)

机构地区：[1]河南省平煤神马医疗集团总医院内分泌二区,河南平顶山467500

出　　处：《中国民康医学》2024年第23期24-27,共4页Medical Journal of Chinese People’s Health

摘　　要：目的:观察胰激肽原酶肠溶片联合依帕司他胶囊治疗糖尿病周围神经病变(DPN)患者的效果。方法:回顾性分析2021年8月至2023年5月该院收治的76例DPN患者的临床资料,依据治疗方案不同将其分为对照组与研究组各38例。对照组予以依帕司他胶囊治疗,研究组在对照组基础上联合胰激肽原酶肠溶片治疗。比较两组临床疗效,治疗前后血液流变学指标(全血高切黏度、血浆黏度、全血低切黏度、血细胞比容)、氧化应激指标[8-羟基脱氧鸟苷酸(8-OHdG)、丙二醛(MDA)、超氧化物歧化酶(SOD)、过氧化氢酶(CAT)]、炎性指标[神经降压肽(PNT)、C-X-C基序趋化因子配体12(CXCL12)、白细胞介素-17A(IL-17A)、C-C基序趋化因子配体2(CCL2)]水平,以及不良反应发生率。结果:研究组治疗总有效率为92.11%(35/38),高于对照组的73.68%(28/38),差异有统计学意义(P<0.05);两组全血高切黏度、血浆黏度、全血低切黏度、血细胞比容均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05);两组8-OHdG、MDA水平均低于治疗前,且研究组低于对照组,两组SOD、CAT水平均高于治疗前,且研究组高于对照组,差异有统计学意义(P<0.05);两组血清PNT水平均高于治疗前,且研究组高于对照组,两组CXCL12、IL-17A、CCL2水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:胰激肽原酶肠溶片联合依帕司他胶囊治疗DPN患者可提高治疗总有效率和血液流变学指标,以及改善氧化应激指标和炎性指标水平的效果优于单纯依帕司他胶囊治疗。Objective:To observe effects of Pancreatic kininogenase enteric-coated tablets combined with Epalrestat capsules in treatment of patients with diabetic peripheral neuropathy(DPN).Methods:The clinical data of 76 patients with DPN admitted to this hospital from August 2021 to May 2023 were retrospectively analyzed.According to different treatment options,they were divided into control group and study group,38 cases in each group.The control group was treated with Epalrestat capsules,while the study group was treated with Pancreatic kininogenase entericcoated tablets on the basis of that of the control group.The clinical efficacy,the levels of hemorheology indexes(whole blood high shear viscosity,plasma viscosity,whole blood low shear viscosity,hematocrit),oxidative stress indexes[8-hydroxydeoxyguanosine(8-OHdG),malondialdehyde(MDA),superoxide dismutase(SOD),catalase(CAT)]and inflammatory factors[neurotensin peptide(PNT),C-X-C motif chemokine ligand 12(CXCL12),interleukin-17 A(IL-17 A),C-C motif chemokine ligand 2(CCL2)]before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of the study group was 92.11%(35/38),which was higher than 73.68%(28/38)of the control group,and the difference was statistically significant(P<0.05).The levels of whole blood high shear viscosity,plasma viscosity,whole blood low shear viscosity and hematocrit in the two groups were lower than those before the treatment,those in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).The levels of 8-OHdG and MDA in the two groups were lower than those before the treatment,and those in the study group were lower than those in the control group;the levels of SOD and CAT in the two groups were higher than those before the treatment,and those in the study group were higher than those in the control group;and the differences were statistically significant(P<0.05).The serum PNT levels of the two groups were

关 键 词：胰激肽原酶肠溶片 依帕司他胶囊 糖尿病周围神经病变 血液流变学 炎性指标 不良反应 

分 类 号：R587.2[医药卫生—内分泌]